Cancer/testis antigen 1 (80-88)

Cancer/testis antigen 1; NY-ESO-1

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.

CAT No: ta-503

Synonyms/Alias:Cancer/testis antigen 1 (80-88);NY-ESO-1 (80-88)

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
Sequence
ARGPESRLL
Areas of Interest
Antigen-presenting Cells; Cancer Research

Cancer/testis antigen 1 (80-88) is a synthetic peptide fragment derived from the cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1, which is recognized for its restricted expression pattern in normal adult tissues and frequent upregulation in a wide range of malignancies. The 80-88 peptide sequence represents a defined epitope within the CTAG1 protein, making it highly relevant for immunological research, especially in the context of tumor immunology and antigen-specific immune response studies. Due to its immunogenic properties and its association with tumor-specific expression, this peptide serves as a valuable tool for dissecting the molecular mechanisms of antigen recognition, T-cell activation, and epitope mapping in cancer research laboratories.

Epitope mapping: Cancer/testis antigen 1 (80-88) is widely employed in epitope mapping studies to delineate the precise regions of CTAG1 recognized by cytotoxic T lymphocytes (CTLs). By using this defined peptide fragment in conjunction with patient-derived or engineered T cells, researchers are able to characterize the immunodominant epitopes that can elicit robust immune responses. This approach is essential for understanding the specificity and breadth of anti-tumor T-cell responses, which informs the selection of peptide candidates for further immunological investigation or translational research.

T-cell activation assays: The 80-88 peptide is instrumental in functional assays designed to assess the activation, proliferation, and cytokine production of T cells specific for CTAG1. By pulsing antigen-presenting cells with this peptide, investigators can monitor T-cell receptor (TCR) engagement, downstream signaling events, and effector functions. Such assays provide critical insights into the immunogenicity of the epitope and support the evaluation of T-cell responses in preclinical models or ex vivo human samples.

Vaccine research: As a well-characterized immunogenic epitope, the Cancer/testis antigen 1 (80-88) peptide is frequently utilized in the development and optimization of experimental cancer vaccines. Its inclusion in peptide-based vaccine formulations allows for the targeted stimulation of antigen-specific CTLs, enabling researchers to evaluate the immunopotency and safety profiles of candidate immunogens. The use of this peptide in vaccine design studies also facilitates the investigation of adjuvants, delivery systems, and epitope combinations that may enhance anti-tumor immunity.

MHC binding studies: The defined sequence of the 80-88 epitope supports its application in major histocompatibility complex (MHC) binding assays. Researchers use this peptide to determine its affinity for various HLA alleles, assess peptide-MHC stability, and model peptide presentation on the cell surface. These studies are essential for predicting epitope immunogenicity, understanding antigen processing pathways, and guiding the rational selection of peptides for immunotherapeutic strategies.

Immunomonitoring: The Cancer/testis antigen 1 (80-88) peptide is a valuable reagent in immunomonitoring protocols that track the presence and functional status of antigen-specific T cells in research samples. By incorporating the peptide into ELISPOT, multimer staining, or intracellular cytokine staining assays, scientists can quantify the frequency and phenotype of CTAG1-reactive T cells in peripheral blood or tumor-infiltrating lymphocyte populations. Such monitoring is crucial for evaluating immune responses in experimental systems and validating the efficacy of immunomodulatory interventions targeting CTAG1.

Source#
Homo sapiens (human)
Epitope
80-88
Restricting HLA
HLA-Cw6
References
Gnjatic; Proc Natl Acad Sci U S A 2000

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
Custom Conjugation ServicePeptide Synthesis ServicesPeptide Modification ServicesPeptide Analysis ServicesEpitope Mapping ServicescGMP Peptide ServicePeptide Nucleic Acids SynthesisPeptide CDMO
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers

Creative Peptides customer logo 1 Creative Peptides customer logo 2 Creative Peptides customer logo 3 Creative Peptides customer logo 4 Creative Peptides customer logo 5 Creative Peptides customer logo 6 Creative Peptides customer logo 7 Creative Peptides customer logo 8 Creative Peptides customer logo 9 Creative Peptides customer logo 10 Creative Peptides customer logo 11 Creative Peptides customer logo 12 Creative Peptides customer logo 13 Creative Peptides customer logo 14 Creative Peptides customer logo 15 Creative Peptides customer logo 16 Creative Peptides customer logo 17 Creative Peptides customer logo 18 Creative Peptides customer logo 19 Creative Peptides customer logo 20 Creative Peptides customer logo 21 Creative Peptides customer logo 22 Creative Peptides customer logo 23 Creative Peptides customer logo 24 Creative Peptides client partner 1 Creative Peptides client partner 2 Creative Peptides client partner 3 Creative Peptides client partner 4 Creative Peptides client partner 5 Creative Peptides client partner 6 Creative Peptides client partner 7 Creative Peptides client partner 8 Creative Peptides client partner 9 Creative Peptides client partner 10 Creative Peptides client partner 11 Creative Peptides client partner 12 Creative Peptides client partner 13 Creative Peptides client partner 14 Creative Peptides client partner 15 Creative Peptides client partner 16 Creative Peptides client partner 17 Creative Peptides client partner 18 Creative Peptides client partner 19 Creative Peptides client partner 20 Creative Peptides client partner 21 Creative Peptides client partner 22 Creative Peptides client partner 23 Creative Peptides client partner 24